Latest filing published 17 Sept 2024 for IGM Biosciences, Inc., €15k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Bruce Keyt is a declared insider of IGM Biosciences, Inc. (senior executive), with filings sourced from SEC (Form 4). We count 36 filings; the first trade dates from 3 May 2021 and the latest from 13 September 2024.
On the market, this insider has only sold: 8 sales, €190k in total. Other entries cover 13 share grants and 15 option exercises. In 2024 alone, the filings show no purchases and 2 sales.
The latest filing, published on 17 September 2024, reports an open-market sale of €15k in IGM Biosciences, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 36 declarations